within Pharmacolibrary.Drugs.ATC.A;

model A16AX02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 0.00016666666666666666,
    adminDuration  = 600,
    adminMass      = 25 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A16AX02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Anethole trithione is a synthetic compound previously used as a choleretic agent to stimulate bile secretion. It has also been investigated for the treatment of dry mouth (xerostomia) in patients with various medical conditions, including Sjögren's syndrome, and as an adjunct therapy in some cancer indications. Its clinical use today is very limited or largely discontinued in most countries.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for a healthy adult oral administration; no direct clinical PK study available for anethole trithione.</p><h4>References</h4><ol><li><p>He, J, et al., &amp; Li, F (2011). An HPLC-MS/MS method for the quantitative determination of 4-hydroxy-anethole trithione in human plasma and its application to a pharmacokinetic study. <i>Journal of pharmaceutical and biomedical analysis</i> 54(3) 551–556. DOI:<a href=\"https://doi.org/10.1016/j.jpba.2010.09.037\">10.1016/j.jpba.2010.09.037</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20980118/\">https://pubmed.ncbi.nlm.nih.gov/20980118</a></p></li><li><p>Huang, S, et al., &amp; Yang, T (2020). Synthesis, Characterization, and In Vivo Evaluation of Desmethyl Anethole Trithione Phosphate Prodrug for Ameliorating Cerebral Ischemia-Reperfusion Injury in Rats. <i>ACS omega</i> 5(9) 4595–4602. DOI:<a href=\"https://doi.org/10.1021/acsomega.9b04129\">10.1021/acsomega.9b04129</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32175506/\">https://pubmed.ncbi.nlm.nih.gov/32175506</a></p></li><li><p>Han, SF, et al., &amp; Gan, Y (2009). Lipid-based formulations to enhance oral bioavailability of the poorly water-soluble drug anethol trithione: effects of lipid composition and formulation. <i>International journal of pharmaceutics</i> 379(1) 18–24. DOI:<a href=\"https://doi.org/10.1016/j.ijpharm.2009.06.001\">10.1016/j.ijpharm.2009.06.001</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19508887/\">https://pubmed.ncbi.nlm.nih.gov/19508887</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A16AX02;
